期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 10, 期 5, 页码 595-604出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2016.1140036
关键词
Esophageal cancer; Targeted therapy; EGFR; HER2; VEGFR; c-MET
资金
- National Natural Scientific Foundation of China [81171923]
- Foundation of Shaanxi Province Science and Technology Research [2012KJXX-20]
- Top Ph.D. Foundation of China [201075]
An increasing number of patients are diagnosed with esophageal cancer at an advanced stages, and only a small group of them can benefit from the traditional chemotherapy and radiotherapy. So far, multiple monoclonal antibodies and tyrosine kinase inhibitors have been developed, alone or in combination with traditional therapy, to improve the prognosis of patients with advanced esophageal cancer. This review summarizes the recent advances of targeted therapies against EGFR, HER2, VEGFR and c-MET in esophageal cancer. More clinical trials should be performed to evaluate the efficacy and safety of various targeted therapy regimens. Future basic research should focus on investigating the molecular mechanisms of therapeutic targets in esophageal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据